Crossmark

Ultrasmall targeted nanoparticles with engineered antibody fragments for imaging detection of HER2-overexpressing breast cancer

Crossref DOI link: https://doi.org/10.1038/S41467-018-06271-5

Published: 2018-12

Update policy: https://doi.org/10.1007/SPRINGER_CROSSMARK_POLICY

Authors

Chen, Feng http://orcid.org/0000-0001-6495-1030
Ma, Kai http://orcid.org/0000-0003-4415-6894
Madajewski, Brian http://orcid.org/0000-0001-6156-0405
Zhuang, Li

Zhang, Li

Rickert, Keith http://orcid.org/0000-0003-0250-298X
Marelli, Marcello http://orcid.org/0000-0001-7095-8263
Yoo, Barney

Turker, Melik Z. http://orcid.org/0000-0001-7801-4275
Overholtzer, Michael

Quinn, Thomas P.

Gonen, Mithat

Zanzonico, Pat

Tuesca, Anthony

Bowen, Michael A.

Norton, Larry

Subramony, J. Anand

Wiesner, Ulrich

Bradbury, Michelle S. http://orcid.org/0000-0003-3147-4391
License Information

Text and Data Mining valid from 2018-10-08
More Information

Article History

Received: 2 July 2018

Accepted: 24 August 2018

First Online: 8 October 2018

Competing interests

: MSK, Cornell, and corresponding authors Michelle Bradbury and Ulrich Wiesner have a financial interest in Elucida Oncology, Inc. The remaining authors declare no competing interests.